Möchten Sie immer auf dem neuesten Stand bleiben?

FDA decision expected within six months of acceptancePivotal phase 3 clinical trial of treosulfan met primary endpoint and key secondary endpoints TORONTO and CHICAGO, July 25, 2022 (GLOBE...

TORONTO and CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update...

TORONTO and CHICAGO, June 14, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 23, 2022...

Study’s primary endpoint and key secondary endpoints were metStudy found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality...

TORONTO and CHICAGO, May 24, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, a strategic partner of Medexus, that medac received...

Additional data collection and analysis reconfirms confidence in New Drug Application for TreosulfanNDA resubmission date consistent with previously announced timelineFDA decision still expected...

TORONTO and CHICAGO, April 19, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) will be presenting at the Bloom Burton & Co. Healthcare Investor Conference...

TORONTO and CHICAGO, March 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that it will be participating in...

Medexus has acquired exclusive rights to commercialize Gleolan in the United States,complementing Medexus’s existing rights to Gleolan in Canada Gleolan is an optical imaging agent currently...

Medexus will implement a NCIB in respect of its6% unsecured convertible debentures due 2023 NCIB will commence on February 16, 2022 and is expected to continue for up to 12 months NCIB purchases...